Vista Current Coverage

All Soligenix Articles

Two Emerging Growth Firms Surged +40% Today!

It was an amazing trading day for two emerging growth biotech stocks that respectively surged more than +40% into the close today on over a combined 45.5 million shares of trading volume! Who are they? The first is Soligenix, Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company...

Soligenix (SNGX) & SciClone (SCLN) Establish Regional Licensing Agreement for SGX942, a Novel Product Candidate for Oral Mucositis

Recently, Soligenix, Inc. (SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, and SciClone Pharmaceuticals, Inc. (SCLN), a US-based China-focused specialty pharmaceutical company, announced today that the companies have entered into an...

Vista Partners Updates Coverage on Soligenix, Inc. (Ticker: SNGX)

Vista Partners announced that it has updated coverage on Soligenix, Inc. (“The Company” or “SNGX”) (Ticker: SNGX), a clinical stage biopharmaceutical company based in Princeton, New Jersey, with a twelve-month price target of $4.50. Ross Silver, Principal Analyst at Vista Partners, stated, “Randal J. Kirk, the...